INTRODUCTION
Graves' disease is a common autoimmune disorder that has a multifaced etiology involving genetic and environmental factors and is featured by the presence of thyroid stimulating hormone receptor (TSHR)-stimulating antibodies (TSAbs) that can promote the function of thyroid follicular cells (TFCs) and stimulate thyroid growth, and thus lead to an overproduction of thyroid hormones (TH). It is reported that worldwide prevalence of Graves' disease (GD) has become popular with an incidence of 1 in 4000 persons per year. GD has generally been viewed to be mediated by a humoral autoimmune response mainly because the infiltration of lymphocytes can activate the TSHR-reactive B cells and lead to the abundant production of TSAbs, manifesting as hyperthyroidism.
Anti-TSHR antibodies, as the diagnostic and therapeutic hallmarks of GD, can be found in 90% of GD patients and mainly belong to IgG1 class involved in the early period of humoral response. IgG exerts the immunoregulatory effects through FcγRs, a well-acknowledged class of cell surface receptors that interact with the Fc domain of IgG. FcγRs are classed into activatory or inhibitory form according to different intracellular signaling motifs. There are three different FcγR classes in human beings including FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16). FcγRIIB is the only known inhibitory FcγR while others are activatory. FcγRs are broadly expressed in almost all hematopoietic cells except T cells. Most cells express activating as well as inhibitory FcγRs with the exception of NK cells (only expressing FcγRII) and B cells (only expressing FcγRIIB). Activation of activatory FcγRs causes immune responses such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), while crosslinking of the inhibitory FcγRIIB such as coggulation of FcγRIIB with BCR can negatively regulate the activation and proliferation of B cell and therefore inhibit IgG production. These three types of FcγRs are all expressed on human monocytes. CD64 is a highly affinitive receptor presented at considerable expression by monocytes. CD32 can also be detected at substantial levels on monocytes, with low affinity of two different isotopes. CD16 is a receptor with average affinity for IgG, which is expressed on approximately 10% of monocytes. Of these FcγRs, CD16, CD32A, and CD64 are activatory Fcγ receptors with intracytoplasmic tyrosine-based activatory motifs that induce monocytes initiation under receptor polymerization. In contrast, CD32B is composed of immunoreceptor tyrosine-based inhibitory motif and serves as the only inhibitory FcγR via interacting with immune complexes.

Autoantibodies are the key serological markers for many autoimmune diseases and also act as potential initiator of inflammation and contribute to disease development. FcγRs distinctly impact antigen intake and processing, cellular activating, and secretion of inflammatory regulators. There have been several studies indicating an involvement of FcγRs in autoimmune diseases like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and immune thrombocytopenia (ITP). Studies on the expression of FcγRs in autoimmune thyroid diseases are scarce. A study about Hashimoto’s thyroiditis recently implied that increasing expression of FcγRIII and decreasing expression of FcγRIIB may be involved in the pathogenesis of HT. The expression of FcγRII from GD patients was reported by Estienne et al, and the authors suggested that FcγRII expressed by thyrocytes might involve in eliminating IgG.

Here, we aimed to investigate the potential role of FcγRs in active and remissive GD patients. The expression of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) on peripheral blood mononuclear cells (PBMCs) and monocytes from GD patients were examined by flow cytometry and Western blotting. The CD32 isotypes (CD32A and CD32B) were studied on PBMCs from cases and controls by real-time PCR as well. Moreover, we also analyzed the correlation between the expression levels of FcγRs with autoantibodies.

## METHODS

### 2.1 Subjects and study group

A total of 76 subjects were enrolled in this study, including 30 patients with GD in active, 16 patients with GD in remission, and 30 age- and sex-matched controls. Patients with active GD were newly diagnosed with no medication before by a standard clinical and laboratory examination, including the history and physical examination, serological detection, and radioactive iodine uptake assay. GD patients in remission had been treated with methimazole for over 3 months, and the clinical characteristic had been dramatically improved compared with those in active patients. All participants had no history of systemic autoimmune disease, chronic disease, or any severe illnesses. The detection of serum thyrotropin (TSH), free T3 (FT3), free T4 (FT4), and thyroid autoantibodies including TPOAb, TgAb, and thyrotrophin receptor antibody (TRAb) was performed using electrochemiluminescent immunoassay with Cobas Elesys 601 (Roche Diagnostics Ltd, Switzerland). All information was listed in Table 1.

### 2.2 Peripheral blood mononuclear cell isolation

Fresh blood was collected in heparinized tubes. The isolation of PBMC was performed by Ficoll-isopaque density gradient

| Variable | HC | GD in active | GD in remission | Normal range |
|----------|----|--------------|-----------------|--------------|
| No.      | 30 | 30           | 16              | --           |
| Age (y)  | 37 ± 8 | 30 ± 9       | 36 ± 5          | --           |
| Gender (M/F) | 4/26 | 5/25         | 3/13            | --           |
| TSH (mIU/L) | 1.96 ± 0.27 | 0.007 ± 0.01 | 2.34 ± 0.35    | 0.35–4.94    |
| FT4 (pmol/L) | 13.4 ± 1.54 | 46.02 ± 14.7 | 15.79 ± 2.15   | 9.01–19.05   |
| FT3 (pmol/L) | 3.18 ± 0.55 | 34.3 ± 6.90  | 3.96 ± 0.71    | 2.63–5.70    |
| TRAb (IU/L) | -- | 27.9 ± 9.52  | 2.3 ± 0.43     | 0–1.75       |
| TPOAb (IU/mL) | 5.03 ± 0.17 | 167.5 ± 23.23 | 24.3 ± 11.62  | 0.11–5.23    |
| TgAb (IU/mL) | 2.54 ± 0.36 | 192.28 ± 17.32 | 47.12 ± 15.97 | 0.81–3.83    |

Note: Data are expressed as means ± standard deviation. M, male; F, female. "--" represents that the experiment was not performed, or the data are not applicable.

Abbreviation(s): GD, Graves’ disease; HC, healthy controls.

| TABLE 1 | The clinical characteristics of patients with Graves’ disease and healthy controls |
centrifugation (Gibco BRL, Life Technologies Ltd) as described previously. About 1 ml Trizol (Invitrogen) was added into cells and stored in –80°C for further use.

2.3  Western blot analysis

Peripheral blood mononuclear cells were homogenized in ice PBS containing 0.05% Triton X-100 and protease inhibitor cocktail (Sigma). Protein samples were run on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Sigma) and transferred onto PVDF membranes according to standard protocol, and then blocked with 5% dried skimmed milk in TBST for at least 1h. The membranes were then incubated overnight at 4°C, either with a mouse monoclonal anti-CD64 antibody and anti-CD32 antibody (1:800; Abcam), a polyclonal rabbit anti-CD16 antibody (1:800; Abcam), or a polyclonal rabbit anti-GAPDH (1:1000; Abcam), and then incubated with horseradish peroxidase-conjugated secondary antibodies (1:1000; Bio-Rad) at room temperature for 1 hour after washing three times using TBST. Blots were washed again and developed using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech). Immunoblot bands quantitation was calculated by means of a Bio-Rad calibrated densitometer (GS-800) using the vendor’s software (Bio-Rad Laboratories); GAPDH was used as an internal reference for analyses.

2.4  Flow cytometric analysis of the proportion of CD64/CD32/CD16 cells on PBMCS and monocytes

Mononuclear cells from the PBMCs were harvested and subsequently stimulated with PMA (Sigma-Aldrich), ionomycin (Sigma-Aldrich), and monensin (BD Biosciences Corp) for 8 hours in a thermostat. The cells were stained with a CD14-FITC monoclonal antibody (eBioscience), and the surface expression of FcγRs on monocytes was investigated by incubating with monoclonal antibodies against CD16-APC (BD Biosciences Corp.), CD32-APC (DAKO), and CD64-APC (BD Biosciences Corp.) for 30 minutes in darkness. Cells were then washed with PBS for three times and fixed in 1% paraformaldehyde. The analysis of samples was performed using a BD FACS Array (Becton-Dickinson) equipped with Cellquest software. Gates for monocytes were set according to forward scatter pattern.

2.5  Quantitative real-time PCR analysis

Total RNA was extracted from PBMC using TRIZO1 (Invitrogen). Reverse transcription was achieved using Takara Kit (RR047A); cDNA amplification was then performed using SYBR Premix Ex Taq (TAKARA, RR820) in Roche 480 Light Cycler. PCR was carried out for 40 cycles according to the following procedure: at 95°C for 30 s, annealing for 30 s, and at 60°C for 34 s. Each sample was analyzed in duplicate. Relative mRNA expression levels of the target genes were calculated using GAPDH as an internal control. The primer sequences used for PCR are shown as Table 2.

2.6  Statistical analysis

All statistical analyses were performed using SPSS Software 20.0 (SPSS, Inc). Results are given as means ± standard deviation. One-way analysis of variance (ANOVA) was used for the comparison of the expression of FcγRs in all three groups. Spearman’s method was used for the correlation analysis between FcγRs and clinical characteristic. GraphPad Prism 5 software was used to analyze data and create graphs. P value < 0.05 was viewed as statistically significant.

3  RESULTS

3.1  Clinical characteristics of Grave’ disease patients in active and in remission and controls

The clinical features and laboratory parameters are presented in Table 1. We enrolled 46 patients (30 initial cases, 16 remissive cases) and 30 age- and gender-matched healthy controls. As shown in Table 1, patients in active group exhibited significantly higher levels of FT3, FT4, TPOAb, TgAb, and TRAb and extremely lower levels of TSH than controls. In addition, patients in remissive group remained euthyroid with greatly improved laboratory parameters as compared with patients in active group.

3.2  Protein expression of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) on peripheral blood mononuclear cells from Grave’ disease in active and in remission and controls

The expression of FcγRs on PBMCs from GD patients and controls was studied by Western blotting. As shown in Figure 1A,B, CD16 expression on PBMCs remained no difference between three groups (P > 0.05, respectively). Moreover, the results also shown that CD64 expression on PBMCs was comparable among GD patients (both initial and remissive) and controls (P > 0.05, respectively; Figure 1A,D). However, as the data presented in Figure 1A,C, GD patients in active revealed a lower expression of CD32 on PBMCs compared to those with GD in remission and controls (P < 0.05, respectively).

| Genes     | Forward primer     | Reverse primer                          |
|-----------|--------------------|----------------------------------------|
| CD32B     | AGCCAACTCCACATCTTGA| GGTGCATGAGGTAGTTAAGTT                |
| CD32A     | GTAAGCTTCGCTTCTTAAACCAC| CAGACGAAAACTGCTAATTGTT             |
| GAPDH     | CAA AGACCTGTACGCCAACA| CAA AGACCTGTACGCCAACA              |
3.3 | The surface expression of CD64, CD32, AND CD16 on PBMCs from GD cases and controls

We examined the surface expression of three FcγRs on PBMCs from patients and healthy subjects by flow cytometry study. As demonstrated in Figure 2A, D, there is no significant difference in the cell percentages of CD64 from patients with GD and controls (14.32 ± 2.03 for GD in active vs. 12.74 ± 2.12 for controls; P > 0.05). In addition, we also could not find difference in the proportion of CD16 among three groups (12.12 ± 2.21 for GD in active vs. 13.74 ± 2.92 for GD in remission vs. 13.54 ± 1.75 for controls; P > 0.05; Figure 2C). However, as demonstrated in Figure 2B, the cell percentages of CD32 were remarkably lower in initial GD group (20.13 ± 3.21) as compared with those in remission (38.72 ± 4.96; P < 0.05) and controls (42.5 ± 5.73; P < 0.05).

3.4 | The expression of CD64, CD32, AND CD16 on monocytes from GD patients and controls

The percentages of CD14+ CD64+ cells, CD14+ CD32+ cells, and CD14+ CD16+ cells were measured in the PBMCs from GD patients in active and in remission and healthy control subjects. As shown in Figure 2A, the cell percentages expressed CD64 in monocytes were comparable between GD patients and control subjects (15.16 ± 2.92 for GD in active vs. 16.37 ± 3.1 for GD in remission vs. 14.25 ± 2.5 for controls; P > 0.05). Moreover, no differences were found in the cell percentages expressed CD16 between patient group and control group (12.91 ± 2.73 for GD in active vs. 14.3 ± 2.11 for GD in remission vs. 13.24 ± 1.55 for controls; P > 0.05; Figure 3C). However, as shown in Figure 3B, the cell proportions expressed CD32 in monocytes were significantly reduced in initial GD patients (11.39 ± 1.41) as compared with patients in remission (21.28 ± 4.53; P < 0.05) and healthy subjects (19.71 ± 3.59; P < 0.05). There was no difference between patients in remission and healthy controls.

3.5 | Association between laboratory parameters and cell percentage of CD14+CD32+ cells in active GD patients

In this study, we also analyzed the association of clinical and laboratory characteristic with the expression of FcγRs. As exhibited in Figure 4, an inverse correlation between the cell percentage of CD14+CD32+ cells and TRAb titers was found in the active patients (r = −0.5825, P < 0.001). No significant relationship was found between laboratory factors and the expression of other FcγRs (P > 0.05).

3.6 | CD32B mRNA expression in PBMCs from GD patients in active and in remission and control subjects

To further determine the role of CD32 subtypes, we analyzed CD32 isotypes in PBMCs from GD patients and controls. As shown in Figure 5A, there was no difference in the mRNA expression of CD32A between GD patients and controls (P > 0.05). However, the mRNA expression of CD32B was significantly lower in patients with initial GD than those with remissive GD and healthy subjects (P < 0.05).
DISCUSSION

The pathogenesis of GD is involved by cellular and humoral factors, and the latter is featured by the presence of TRAbs. The involvement of autoantibodies to promote autoimmunity greatly depends on their ability to engage with Fcγ receptors which are expressed by immune cells. FcγRs are contributed to binding immune complexes and transmitting signaling and subsequently affect cellular functions.18 The interplay between pathogen-dependent IgG and the activation of FcγRs regulates pathogen elimination via ADCC and the reduction of cytotoxic cells and exerts a crucial role in secreting cytokines and inflammatory regulators.6 FcγRIIB can inhibit all the processes and therefore downregulates immune complex-mediated cellular activation.19 Hence, the FcγRs are pivotal to the immune system via exerting different functions.

FcγRs were found to be involved in many autoimmune diseases including SLE, RA. So far, limited data are yet available regarding FcγRs expression from PBMCs and monocytes in GD. In this study, we reported for the first time that decreased cell percentages expressed FcγRII (CD32) as well as decreased protein levels of FcγRII from PBMCs and monocytes have been found in patients with active GD patients by using flow cytometry and Western blotting, and we further verified the isotype of CD32 was CD32B. Our result was consistent with the previous study, which found that the expression of CD32 was reduced in PBMC from HT patients,15 suggesting that the upregulated antibody-dependent cellular cytotoxicity was activated in AITD. The pathology of GD is involved by both Th1- and Th2-mediated immune activity. The reduction of CD32 in PBMCs and monocytes in this study may partly be explained by the influence of inflammatory cytokines since both Th1 cytokines (TNF-α and IFN-γ) and Th2 cytokines (IL-4 and IL-10) can affect the expression of FcγRs.9,20 It was reported that CD32B expression was increased by IL-4 and decreased by IFN-γ while CD32A was decreased by IL-4 and increased by IFN-γ.9 Although GD was mainly viewed as a predominant Th2-mediated immune response, the infiltration in the intrathyroidal of both Th1 and Th2 cells also suggested a role of Th1 cytokines. The shift of Th1-Th2 balance may contribute to the aberrant expression of CD32. Besides, abnormal clearance of immune complexes and apoptotic fragment in GD might also involve in the expression of CD32.21 In summary, the imbalance between cellular immunity and the cytokines production in GD patients was involved in the reduction of CD32B in monocytes, which might ultimately
aggravate the process of GD via several regulations to different cells. More researches are needed to illuminate this theory.

In our study, we found CD64 expression on PBMCs and monocytes were comparable between patients and controls. The expression of CD64 on monocytes has been examined in SLE patients and was found to be increased in active systemic inflammation and be related to the development of nephritis. In addition, we also found cell percentages expressed CD16 were also similar among three groups, which was inconsistent with those in HT study. This discrepancy may due to the lower patients’ number and the different mechanism between HT and GD. Further studies are needed to clarify these results.

To date, this is the first report to study CD32 isotypes in PBMCs from GD patients. Our results showed that the expression of CD32B on PBMCs was reduced in active GD patients, which was consistent with other studies on CD32B expression in patients with RA and SLE. Previous study also showed that the CD32B expression on B cells was reduced in HT and SLE patients. CD32B can

FIGURE 3 The percentage of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) on monocytes from Grave’s disease (GD) in active and in remission and controls by flow cytometric analysis. A, Bar graphs from three groups depicting cell percentage of CD64-enriched monocytes (left panels). B, Bar graphs from three groups depicting cell percentage of CD32-enriched monocytes (middle panels). C, Bar graphs from three groups depicting cell percentage of CD16-enriched monocytes (right panels). D, Flow cytometry dot plots from three groups depicting CD32 expression by CD14-enriched monocyte cells. The number in the right quadrants represents the percentage of CD14+CD32" in each group. Data are presented as the means ± standard error. One-way ANOVA was used to compare the differences in multiple groups. P < 0.05 was considered significant. GD, Graves' disease.

FIGURE 4 Correlation analysis of laboratory parameters and cell percentage of CD14"CD32" cells in active GD patients. Association between CD32 expression by CD14-enriched monocyte cells and TRAb in GD patients. The correlation between CD14"CD32" and clinical characteristic was analyzed with Spearman’s method. TRAb, TSH receptor antibody; GD, Graves’ disease.
prevent antibody-mediated autoimmunity through regulating different cellular function—by reducing the production of autoantibodies via effects on B cells, by limiting the autoantibody-dependent inflammation via influencing macrophages and neutrophils, and by prohibiting immune-complexed autoantigen presentation to autoreactive T cells. The over-secretion of CD32B by B cells has been shown to reduce the incidence of SLE mouse model. It has been reported that CD32B was increased on dendritic cells in untreated RA subjects with a low disease activity. Studies focused on FcγRs expression of thyrocytes from AITD suggested CD32B and FcRn may participate in the autoantigen presenting. Our study here demonstrated that the expression of inhibitory CD32B from PBMC was also downregulated in GD patients, providing further evidence to confirm CD32B could be involved in the pathogenesis of GD.

In the present study, we found the expression of CD32 on monocytes from active GD patients was negatively correlated with the TRAb titers, indicating that the expression of CD32 may be associated with disease activity. This correlation was consistent with Yuasa's study that FcγRIIB-deficient mice have elevated collagen-specific IgG titers and have shown severer disease activity in collagen-induced arthritis. One of the unique characteristics of GD is the presence of TSHR antibodies owing to the breakdown of immunity tolerance. In patients with GD, TSHR-reactive B cells survive deletion and potentially present thyroid autoantigen to T cells inducing proinflammatory cytokines. This correlation between the expression of CD32 on monocytes and TRAb titers supported that CD32 played a central role in antibody-mediated autoimmune disease through antibody-dependent mechanism.

5 | CONCLUSION

In this study, we showed for the first time that GD patients in active had a reduced CD32 expression on monocytes. The effective CD32 isotype on GD patients was CD32B. In addition, the expression of CD32 was negatively correlated with TRAb titer in active GD patients. These results suggest that CD32 may act as a novel marker for activated GD. The monocytic CD32, in particular CD32B, in GD patients might play a crucial role in the pathogenesis of GD and could be a therapeutic target.

ACKNOWLEDGMENTS

This study was supported by the Chinese National Natural Science Foundation (grants 81400777, 81570708), the Doctoral Scientific Research start-up Foundation of Liaoning Province (grant 201501042, 201601132), the Excellent Youth Scientific program in China Medical University (grant YQ20170007), and the Program for Liaoning Excellent Talents in University (grant LJQ2015115).

ETHICAL APPROVAL

This study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University, and all participants signed informed consents before any performances. All procedures were in compliance with the ethical standards and with the 1964 Helsinki declaration and its later amendments.

ORCID

Xixuan Lu https://orcid.org/0000-0002-1251-1217

REFERENCES

1. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174-180.
2. Struja T, Kutz A, Fischli S, et al. Is Graves’ disease a primary immunodeficiency? New immunological perspectives on an endocrine disease. BMC Med. 2017;15(1):174.
3. Hasham A, Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res. 2012;54(1-3):204-213.
4. Frohlich E, Wahl R. Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol. 2017;8:521.
5. Vogelpoel LT, Baeten DL, de Jong EC, den Dunnen J. Control of cytokine production by human Fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. 2015;6:79.

6. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.

7. Salmon JE, Pricop L. Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum. 2001;44(4):739-750.

8. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81(3):584-592.

9. Pricop L, Redecha P, Teillaud JL, et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. Journal of immunology. 2001;166(1):531-537.

10. Hepburn AL, Mason JC, Davies KA. Expression of Fc gamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford). 2004;43(5):547-554.

11. Clavel C, Nogueira L, Laurent L, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fc gamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 2008;58(3):678-688.

12. Li Y, Lee PY, Kellner ES, et al. Monocyte surface expression of Fc gamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(3):R90.

13. Su K, Yang H, Li X, et al. Expression profile of Fc gammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007;178(5):3272-3280.

14. Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev. 2008;22(2):103-116.

15. Liu Y, Liu M, Zhang Y, et al. The expression of Fc gamma receptors in Hashimoto’s thyroiditis. Cell Immunol. 2015;294(1):33-38.

16. Estienne V, Duthoit C, Reichert M, et al. Androgen-dependent expression of Fc gammaRIB2 by thyrocytes from patients with autoimmune Graves’ disease: a possible molecular clue for sex dependence of autoimmune disease. FASEB J. 2002;16(9):1087-1092.

17. Radhika A, Jacob SS, Sudhakaran PR. Influence of oxidatively modified LDL on monocyte-macrophage differentiation. Mol Cell Biochem. 2007;305(1-2):133-143.

18. Isaak A, Gergely P Jr, Szekeres Z, et al. Physiological up-regulation of inhibitory receptors Fc gamma RII and CR1B on memory B cells is lacking in SLE patients. Int Immunol. 2008;20(2):185-192.

19. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10(5):328-343.

20. Zhao C, Gao Y, Zhao L, et al. The expression and function of the neonatal Fc receptor in thyrocytes of Hashimoto’s thyroiditis. Int Immunopharmacol. 2017;44:59-60.

21. Wijngaarden S, van de Winkel JG, Jacobs KM, Blijrma JW, Lafeber FP, van Roon JA. A shift in the balance of inhibitory and activating Fc gamma receptors on monocytes toward the inhibitory Fc gamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum. 2004;50(12):3878-3887.

22. Li Y, Lee PY, Solbel ES, et al. Increased expression of Fc gammaRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. Arthritis Res Ther. 2009;11(1):R6.

23. Prokopec KE, Rhodiner M, Matt P, Lindqvist U, Kleinau S. Down regulation of Fc and complement receptors on B cells in rheumatoid arthritis. Clin Immunol. 2010;137(3):322-329.

24. Mackay M, Stanevsky A, Wang T, et al. Selective dysregulation of the FcgammainIB receptor on memory B cells in SLE. J Exp Med. 2006;203(9):2157-2164.

25. Espeli M, Smith KG, Clatworthy MR, Fc gammaRIIB and autoimmunity. Immunol Rev. 2016;269(1):194-211.

26. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science. 2005;307(5709):590-593.

27. Magnusson SE, Wenneberg E, Matt P, Lindqvist U, Dysregulated Fc. Fc receptor function in active rheumatoid arthritis. Immunol Lett. 2014;162(1 Pt A):200-206.

28. Yuasa T, Kubo S, Yoshino T, et al. Deletion of fgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med. 1999;189(1):187-194.

29. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease. Immunol Res. 2012;54(1-3):191-203.

How to cite this article: Lu X, Peng S, Wang X, Shan Z, Teng W. Decreased expression of FcyRII in active Graves’ disease patients. J Clin Lab Anal. 2019;33:e22904. https://doi.org/10.1002/jcla.22904